Press Releases for MNKD

Press Releases
MannKind Announces Completion of Common Stock Offering
MannKind to Present at the 29th Annual Canaccord Adams Global Growth Conference
MannKind Announces Pricing of Public Offering of Common Stock
MannKind Corporation Reports Second Quarter Financial Results
MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2009
MannKind Announces Positive New Market Survey Information Regarding AFRESA®
BenchmarkJournal.Com Free Analyst Review for GAP, ATU, PPHM, MNKD, HLIT and COCO
MannKind Closes Acquisition of Insulin Assets from Pfizer
MannKind Unveils Next-Generation Inhalation System
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
MannKind to Present at the Needham Life Sciences Conference
MannKind to Present at the Canaccord Adams Diabetes and Obesity Conference
MannKind Corporation Reports First Quarter of 2009 Financial Results
MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
MannKind Submits NDA for AFRESA for Treatment of Diabetes
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
MannKind Updates Status of NDA Submission for AFRESA
Zacks Analyst Blog Highlights: Fannie Mae, Freddie Mac, Transocean, Inc., Avon Products and MannKind Corporation.
MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
MannKind Reports Successful Completion of Device Bioequivalence Trial
MannKind to Present at the 27th Annual J.P. Morgan Healthcare Conference
MannKind Reports Top-Line Results from Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
BioBlocks and MannKind Continue Drug Discovery Partnership, Find Close Collaboration Key to Meeting Milestones
MannKind Corporation Reports Third Quarter Financial Results
MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy
MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
MannKind to Present at the UBS Global Life Sciences Conference
MannKind Corporation to Host Webcast Analyst Day September 16, 2008
MannKind Corporation Reports Second Quarter Financial Results
MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
BeaconEquity.com Issues Technical Trade Alerts on Market Movers: EXXI, IVAN, AXAS, MNKD, CYTK, SIRI
BeaconEquity.com Issues TraderNotes on Active Stocks: NLN, GRVY, MDTL, ENER, BTRX, MNKD, ALTI, BG
MannKind to Present at Upcoming Conferences - Jun 16 2008 6:26PM
The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement - Jun 2 2008 1:23AM
MannKind to Present at the Morgan Stanley Healthcare Conference
MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
MannKind Addresses Pfizer's Announcement Regarding Exubera
BellwetherReport.com Free Analyst Review for NKTR, MNKD, EPMD and AMGI